JP2022520080A5 - - Google Patents

Info

Publication number
JP2022520080A5
JP2022520080A5 JP2021546888A JP2021546888A JP2022520080A5 JP 2022520080 A5 JP2022520080 A5 JP 2022520080A5 JP 2021546888 A JP2021546888 A JP 2021546888A JP 2021546888 A JP2021546888 A JP 2021546888A JP 2022520080 A5 JP2022520080 A5 JP 2022520080A5
Authority
JP
Japan
Prior art keywords
nucleic acid
gene
adenosine
base editor
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546888A
Other languages
English (en)
Japanese (ja)
Other versions
JP7586601B2 (ja
JP2022520080A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018073 external-priority patent/WO2020168051A1/en
Publication of JP2022520080A publication Critical patent/JP2022520080A/ja
Publication of JP2022520080A5 publication Critical patent/JP2022520080A5/ja
Priority to JP2024193416A priority Critical patent/JP2025032080A/ja
Application granted granted Critical
Publication of JP7586601B2 publication Critical patent/JP7586601B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546888A 2019-02-13 2020-02-13 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 Active JP7586601B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024193416A JP2025032080A (ja) 2019-02-13 2024-11-05 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962805271P 2019-02-13 2019-02-13
US62/805,271 2019-02-13
US201962850919P 2019-05-21 2019-05-21
US62/850,919 2019-05-21
US201962852224P 2019-05-23 2019-05-23
US201962852228P 2019-05-23 2019-05-23
US62/852,228 2019-05-23
US62/852,224 2019-05-23
US201962873138P 2019-07-11 2019-07-11
US62/873,138 2019-07-11
US201962888867P 2019-08-19 2019-08-19
US62/888,867 2019-08-19
US201962931722P 2019-11-06 2019-11-06
US62/931,722 2019-11-06
US201962941569P 2019-11-27 2019-11-27
US62/941,569 2019-11-27
US202062966526P 2020-01-27 2020-01-27
US62/966,526 2020-01-27
PCT/US2020/018073 WO2020168051A1 (en) 2019-02-13 2020-02-13 Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193416A Division JP2025032080A (ja) 2019-02-13 2024-11-05 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法

Publications (3)

Publication Number Publication Date
JP2022520080A JP2022520080A (ja) 2022-03-28
JP2022520080A5 true JP2022520080A5 (cg-RX-API-DMAC7.html) 2023-02-21
JP7586601B2 JP7586601B2 (ja) 2024-11-19

Family

ID=72045106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546888A Active JP7586601B2 (ja) 2019-02-13 2020-02-13 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法
JP2024193416A Pending JP2025032080A (ja) 2019-02-13 2024-11-05 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024193416A Pending JP2025032080A (ja) 2019-02-13 2024-11-05 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法

Country Status (8)

Country Link
US (1) US20230140953A1 (cg-RX-API-DMAC7.html)
EP (1) EP3924484A4 (cg-RX-API-DMAC7.html)
JP (2) JP7586601B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210127206A (cg-RX-API-DMAC7.html)
CN (2) CN114040970B (cg-RX-API-DMAC7.html)
AU (1) AU2020223306B2 (cg-RX-API-DMAC7.html)
CA (1) CA3128876A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020168051A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3765615T3 (pl) 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
WO2019222555A1 (en) 2018-05-16 2019-11-21 Arbor Biotechnologies, Inc. Novel crispr-associated systems and components
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
CN114096666B (zh) 2019-02-13 2025-03-18 比姆医疗股份有限公司 治疗血红素病变的组合物和方法
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
CN114040970B (zh) * 2019-02-13 2024-09-27 比姆医疗股份有限公司 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法,包括遗传性疾病的治疗
CA3136735A1 (en) 2019-04-15 2020-10-22 Edigene Inc. Methods and compositions for editing rnas
AU2020313143B2 (en) 2019-07-12 2024-04-04 Peking University Targeted RNA editing by leveraging endogenous adar using engineered RNAs
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
AU2020418228A1 (en) * 2019-12-30 2022-08-18 Edigene Therapeutics (Beijing) Inc. Leaper technology based method for treating MPS IH and composition
CN116113692A (zh) * 2020-02-13 2023-05-12 比姆医疗股份有限公司 用于植入碱基编辑细胞的组合物和方法
WO2022027035A1 (en) * 2020-07-27 2022-02-03 The Children's Hospital Of Philadelphia In utero and postnatal gene editing and therapy for treatment of monogenic diseases, including mucopolysaccharidosis type 1h and other disorders
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
US20240110177A1 (en) * 2020-10-21 2024-04-04 The Board Of Trustees Of The Leland Stanford Junior University A screening platform for adar-recruiting guide rnas
EP4323501A1 (en) * 2021-04-16 2024-02-21 Beam Therapeutics Inc. Genetic modification of hepatocytes
CN117729931A (zh) * 2021-05-14 2024-03-19 比姆医疗股份有限公司 用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法
CA3220738A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
EP4426821A1 (en) * 2021-11-02 2024-09-11 University of Massachusetts Nme2cas9 inlaid domain fusion proteins
JP2024543208A (ja) * 2021-12-01 2024-11-19 シェイプ セラピューティクス インコーポレイテッド Lrrk2を標的としたrna編集のための遺伝子操作されたガイドrna及びポリヌクレオチド
CN117187220A (zh) * 2022-03-08 2023-12-08 中国科学院遗传与发育生物学研究所 腺嘌呤脱氨酶及其在碱基编辑中的用途
CN114686456B (zh) 2022-05-10 2023-02-17 中山大学 基于双分子脱氨酶互补的碱基编辑系统及其应用
CA3266991A1 (en) * 2022-09-08 2024-03-14 The University Court Of The University Of Edinburgh TREATMENT OF RETT SYNDROME
WO2024230760A1 (zh) * 2023-05-09 2024-11-14 北京齐禾生科生物科技有限公司 一种可作用于dna的腺苷脱氨酶及其应用
WO2024233941A1 (en) * 2023-05-11 2024-11-14 Massachusetts Eye And Ear Infirmary Base editing approaches to treat abca4-associated stargardt disease
EP4713348A1 (en) * 2023-05-15 2026-03-25 University of Georgia Research Foundation, Inc. Doubly constrained peptides as allosteric inhibitors of leucine rich repeat kinase 2
CN117965505A (zh) * 2023-06-28 2024-05-03 微光基因(苏州)有限公司 工程化的腺苷脱氨酶及碱基编辑器
CN120536418A (zh) * 2024-02-26 2025-08-26 尧唐(上海)生物科技有限公司 一种脱氨酶变体、包含其的碱基编辑器及其应用
WO2025184515A1 (en) * 2024-02-29 2025-09-04 Vesigen, Inc. Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells and tissues of the eye

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012004778A1 (en) * 2010-07-09 2012-01-12 Ecole Polytechnique Federale De Lausanne (Epfl) Method for in-vitro monitoring of neuronal disorders and use thereof
AU2015332533B2 (en) * 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
KR20240007715A (ko) * 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
KR102678809B1 (ko) * 2017-05-18 2024-06-26 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
CN111328290A (zh) * 2017-06-26 2020-06-23 博德研究所 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法
CN109306361B (zh) * 2018-02-11 2022-06-28 华东师范大学 一种新的a/t到g/c碱基定点转换的基因编辑系统
CN109295186B (zh) * 2018-09-30 2023-10-03 中山大学 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用
CN114040970B (zh) * 2019-02-13 2024-09-27 比姆医疗股份有限公司 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法,包括遗传性疾病的治疗

Similar Documents

Publication Publication Date Title
JP2025032080A5 (cg-RX-API-DMAC7.html)
Hom et al. Deep mutational scan of the highly conserved influenza A virus M1 matrix protein reveals substantial intrinsic mutational tolerance
Tsai et al. Addition of m6A to SV40 late mRNAs enhances viral structural gene expression and replication
Meijer et al. φ29 family of phages
Feng et al. Substrate specificity of human protein arginine methyltransferase 7 (PRMT7): the importance of acidic residues in the double E loop
BR112020006786A2 (pt) composições e métodos para editar rna
JP2022545950A5 (cg-RX-API-DMAC7.html)
Mathews Viral evasion of cellular defense mechanisms: regulation of the protein kinase DAI by RNA effectors
JPH05506997A (ja) オリゴヌクレオチドによるインフルエンザウィルス複製の阻止
JP2010528617A5 (ja) リボスイッチならびにリボスイッチを使用するためのおよびリボスイッチと共に使用するための方法および組成物
EP3212788A2 (en) Compositions, methods and use of synthetic lethal screening
Ren et al. Current progress on host antiviral factor IFITMs
Florian et al. Characterization of the anti‐HBV activity of HLP1–23, a human lactoferrin‐derived peptide
Huang et al. Involvement of the zinc-binding capacity of Sendai virus V protein in viral pathogenesis
CN121079310A (zh) 用于治疗与cdkl5缺乏相关的病症的组合物及方法
FR2780069A1 (fr) Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
Jordan-Paiz et al. Impact of synonymous genome recoding on the HIV life cycle
Zhang et al. RING finger protein 5 is a key anti-FMDV host factor through inhibition of virion assembly
KR20110049749A (ko) 양성-센스 단일-사슬 rna 바이러스로의 감염을 예방 또는 치료하기 위한 대형 인간 2´,5´-올리고아데닐레이트 합성효소 oas3
Schotte et al. Characterization of poliovirus neutralization escape mutants of single-domain antibody fragments (VHHs)
EP4008343A2 (en) Methods and compositions related to increased viral production
Tian et al. AntiV‐SGN: a universal antiviral strategy to combat both RNA and DNA viruses by destroying their nucleic acids without sequence limitation
Baquero-Perez et al. From A to m6A: The Emerging Viral Epitranscriptome. Viruses 2021, 13, 1049
CN110214013A (zh) 抗病毒剂及治疗病毒感染的方法
Roos Pathogenesis of Theiler’s murine encephalomyelitis virus‐induced disease